Ophidion
Bethlehem, US · 2 known investors
Find your way into Ophidion
16 people in our graph share verified history with the Ophidion team — schools, employers, funds. One of them is your warm intro.
David Kaufmanunlockedknows Julie Miwa · together at The Rockefeller University
×11knows the team · via The Rockefeller University
Ophidion is an early-stage CNS biopharmaceutical company developing a non-invasive carrier technology that delivers gene-silencing agents and other therapeutics across the blood-brain barrier into the brain. It is building a pipeline of disease-modifying and symptomatic treatments for neurodegenerative diseases, including Huntington's disease and cognition-related conditions.
Founders & leadership
JM
Julie MiwainFounderJulie Miwa is a translational neuroscientist with expertise in nicotinic receptor biology, now serving as Director and Promoter of Ophidion, an early-stage biopharmaceutical company developing gene-silencing therapeutics for neurodegenerative diseases.
YH
Yacoub HabibNamed on SEC filing
Board
ML
Michael LarkBoard director
SF
Scott FishmanBoard director
CB
Claudine BruckBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$4M disclosed across 3 rounds · 2019–2024
▶$655.2KraisedOct 2024 · 8 investors · PharmaceuticalsRule 506(b)
▶$655.2KraisedOct 2024 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael LarkDirector
- Yacoub HabibExecutive Officer, Director, Promoter
- Julie MiwaDirector, Promoter
- Scott FishmanDirector
- Claudine BruckDirector
- Offering amount
- $1.2M
- Amount sold
- $655.2K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedSep 2023 · 8 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedSep 2023 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Julie MiwaDirector, Promoter
- Michael W. LarkDirector
- Scott FishmanDirector
- Claudine BruckDirector
- Yacoub HabibExecutive Officer, Promoter
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedJan 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$1.7MraisedJan 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Yacoub HabibExecutive Officer, Promoter
- Julie MiwaDirector, Promoter
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapAlexion Pharmaceuticals12 shared keywordsAlexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
Viridian Therapeutics9 shared keywordsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Maxion Therapeutics Website9 shared keywordsMaxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs. It focuses on first-in-class and best-in-class treatments for diseases driven by ion channel and GPCR dysfunction, including pain, autoimmune and cardiovascular conditions.
Vividion Therapeutics9 shared keywordsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
Companies competing with Ophidion for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Ophidion do?
- Ophidion is an early-stage CNS biopharmaceutical company developing a non-invasive carrier technology that delivers gene-silencing agents and other therapeutics across the blood-brain barrier into the brain. It is building a pipeline of disease-modifying and symptomatic treatments for neurodegenerative diseases, including Huntington's disease and cognition-related conditions.
- Who founded Ophidion?
- Ophidion was founded by Julie Miwa.
- Who are Ophidion's investors?
- Ophidion's investors include Eisai Innovation, Inc., Robin Hood Ventures.
- How much funding has Ophidion raised?
- Ophidion has disclosed $4M raised across 3 rounds.
- Where is Ophidion headquartered?
- Ophidion is headquartered in Bethlehem, US.